摘要
目的:探讨综合干预模式对注射用核糖核酸Ⅱ临床使用的干预效果,为肿瘤治疗辅助药管理提供参考。方法:通过建立评价标准、病历点评、成立肿瘤治疗辅助药管理工作组、药物与处方权分级、超说明书用药审批、加强考核和培训、临床药师参与等方式,干预注射用核糖核酸Ⅱ的临床使用;并对我院2015年4-6月(干预前)、2015年7-9月(第1次干预后)、2015年10-12月(第2次干预后)、2016年1-3月(第3次干预后)注射用核糖核酸Ⅱ的使用情况进行统计分析。结果:干预前我院注射用核糖核酸Ⅱ的合理使用率仅为77.34%,第1次、第2次、第3次干预后分别上升至83.25%、83.64%和95.12%,与干预前比较差异均有统计学意义(P<0.05)。不合理使用类型包括适应证不适宜、疗程不适宜、用法用量不适宜和联合用药不适宜等,分别由干预前的2.96%、4.93%、13.79%和0.99%下降至第3次干预后的1.63%、0、3.25%和0。注射用核糖核酸Ⅱ的使用率由干预前的8.81%下降至第3次干预后的3.93%,差异有统计学意义(P<0.05)。结论:多种干预方法相结合的综合干预模式,可促进注射用核糖核酸Ⅱ的合理使用,建议进一步研究和评价该模式对其他肿瘤治疗辅助药的干预效果。
OBJECTIVE： To explore the effect of comprehensive intervention mode on the rational use of Ribonucleic acid Ⅱ for injection, and to provide reference for the management of adjuvant drugs for cancer therapy. METHODS： The rational use of ribonucleic acid Ⅱ was interfered by establishing evaluation criteria, reviewing medical record, establishing tumor therapy adjuvant management work group, classifying drug prescription right, examining and approving off-label drug use, strengthening the assess- ment and training, clinical pharmacists intervention. The utilization of ribonucleic acid Ⅱ was analyzed statistically in our hospital during Apr.-Jun. 2015 （before intervention）, Jul.-Sept. 2015 （after the first intervention）, Oct.-Dec. 2015 （after the second interven- tion） and Jan.-Mar. 2016 （after the third intervention）. RESULTS： The reasonable rate of Ribonucleic acid Ⅱ for injection was 77.34% before intervention, and 83.25%, 83.64%, 95.12% after the first, second and third intervention respectively; the difference was statistically significant compared to before intervention （P〈0.05）. The irrational types included inappropriate indications, unsuitable treatment course, inappropriate usage and dosage, and unsuitable drug combination, etc. The percentage of these irratio- nal types decreased from 2.96%, 4.93%, 13.79% and 0.99% before intervention to 1.63%, 0, 3.25% and 0 after the third inter- vention, respectively. The utilization rate of Ribonucleic acid Ⅱ for injection was reduced from 8.81% before intervention to 3.93 % after the third intervention, the differences were statically significant （P〈 0.05）. CONCLUSIONS ： The comprehensive inter- vention model combined with multiple intervention methods can promote the rational use of Ribonucleic acid Ⅱ for injection. It is suggested to further study and evaluate the intervention effect of this model on other adjuvant drugs for cancer therapy.
出处
《中国药房》
CAS
北大核心
2017年第32期4572-4576,共5页
China Pharmacy
基金
江苏现代医院管理中心课题(No.JSY-3-2017-033)
常州市肿瘤医院院级科技项目(No.SY201717)
关键词
注射用核糖核酸Ⅱ
合理用药
肿瘤治疗辅助药
Ribonucleic acid Ⅱ for injection
Rational drug use
Adjuvant drugs for cancer therapy
